NCT07025681View on ClinicalTrials.gov

PK, PD, Safety and Immunogenicity Study of Erythropoietin of Incepta Pharmaceuticals Ltd With Eprex (Janssen-Cilag).

PHASE3RecruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

April 24, 2025

Primary Completion Date

September 30, 2025

Study Completion Date

December 31, 2025

Conditions
Healthy
Interventions
BIOLOGICAL

Erythropoietin alfa

Erythropoietin 4000 IU Injection, for subcutaneous injection.

Trial Locations (1)

1215

RECRUITING

Universal Medical College and Hospital, Dhaka

Sponsors
All Listed Sponsors
collaborator

Institute for Developing Science and Health Initiatives, Bangladesh

OTHER

lead

Incepta Pharmaceuticals Ltd

INDUSTRY